ABL Europe SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ABL Europe SAS - overview
Established
2015
Location
Illkirch-Graffenstaden, -, France
Primary Industry
Biotechnology
About
Based in Illkirch-Graffenstaden, France, and founded in 2015, ABL Europe SAS, a. k. a. ABL Biomanufacturing, operates as a Contract Development and Manufacturing Organization (CDMO) that focuses on scale-up and GMP manufacturing of oncolytic and immunotherapeutic viral vectors.
In December 2023, Oxford BioMedica plc, a portfolio company of Novo Holdings, agreed to acquire ABL Europe SAS from Institut Mérieux and EXOR for approximately EUR 15 million. The company provides a wide range of viral vectors, including Vaccinia, MVA, Adeno, Measles, ORF, Arenavirus, AAV, and others. As of December 2023, ABL Europe works on more than 10 cell and gene therapy programs spanning disease areas, including more than six different vector types.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.abl-biomanufacturing.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
ABL Europe SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | ABL Europe SAS | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.